In a significant development for maternal health, a comprehensive study from Denmark has found no association between the use of Tylenol—known as acetaminophen in many parts of the world—and autism diagnoses in children. This research, published in *Jama Pediatrics*, arrives amidst heightened scrutiny and misinformation regarding the medication’s safety during pregnancy, particularly following controversial claims from political figures.
Key Findings of the Danish Study
Utilising Denmark’s extensive national health registry, researchers tracked the health outcomes of over 1.5 million children born between 1997 and 2022. This impressive dataset included 31,098 children who had been exposed to Tylenol in utero. The findings revealed that autism was diagnosed in 1.8% of children whose mothers took Tylenol during pregnancy, compared to 3% in those who did not.
These results stand in contrast to a previous Swedish study conducted in 2024, which suggested a minimal link that vanished when accounting for genetic factors among siblings—indicating that autism has a significant hereditary component. A review conducted in the United States in 2025 had hinted at potential correlations but did not establish a clear causal relationship, leaving room for interpretation regarding external influences.
Political Influence and Public Perception
The narrative surrounding Tylenol’s safety has been complicated by statements from the Trump administration, which pointed to a supposed link between Tylenol use during pregnancy and an increased risk of autism. This rhetoric prompted a notable decline in the use of acetaminophen among expectant mothers. Following a public announcement from health officials in September 2025 regarding a proposed label change for Tylenol—citing a potential autism link—emergency room orders for the medication among pregnant women plummeted by 16% in the subsequent weeks.
Jeremy Faust, a co-author of a related study published in *The Lancet*, highlighted the adverse impact of such public health messaging, noting that the rate of Tylenol orders fell as dramatically as 20% shortly after the announcement. The decline was not observed in other medications, indicating a specific concern surrounding Tylenol.
Medical Recommendations and Alternatives
Healthcare professionals continue to advocate for the use of Tylenol as a safe option for pain relief and fever reduction during pregnancy. Faust reiterated its status as the safest choice, particularly when compared to non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, which pose risks of bleeding and complications with the placenta.
Moreover, Faust expressed relief that there was no spike in the use of opioids for pain management during the period following the announcement, recognising the importance of addressing pain effectively while minimising risks to both mother and child.
The Broader Context of Health Communication
The September press conference also announced that leucovorin, a B vitamin, could be considered for autism treatment—a claim that was later retracted, underscoring the challenges health officials face in delivering clear and effective public health messaging. The confusion surrounding Tylenol has highlighted the critical need for accurate communication regarding medication safety during pregnancy.
Why it Matters
This study’s findings are crucial not only for expectant mothers but also for public health policy. The misinformation surrounding Tylenol has led to a tangible decrease in its use among pregnant women, potentially putting them at risk for unmanaged pain and fever. As health officials grapple with the consequences of political rhetoric on medical practices, it is imperative to ensure that mothers have access to safe and effective treatments during pregnancy. The evidence, as presented by the Danish study, reinforces the importance of relying on scientific research over anecdotal claims, ultimately safeguarding maternal and child health.
